SCHEMBL473707

SCHEMBL473707

O=C=NCCCCCN1C(=O)C=CC1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 10/20 0.63
FAAH O00519 5/20 0.63
ALDH1A1 P00352 2/20 0.63
LMNA P02545 2/20 0.63
MAPT P10636 2/20 0.63
NPSR1 Q6W5P4 2/20 0.63
HSP90AA1 P07900 1/20 0.63
TLR9 Q9NR96 1/20 0.63
TP53 P04637 1/20 0.63
PKM P14618 1/20 0.63
HPGD P15428 1/20 0.63
XBP1 P17861 1/20 0.63
MAPK1 P28482 1/20 0.63
HTT P42858 1/20 0.63
RECQL P46063 1/20 0.63
RAB9A P51151 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
GPR35 Q9HC97 1/20 0.63
GPR55 Q9Y2T6 1/20 0.63
PTGS1 P23219 7/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4589798 1.00 MGLL (0.63) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL4589431 0.92 MGLL (0.58) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL18952969 0.84 MGLL (0.50) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL26107057 0.82 MGLL (0.37) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL1985393 0.82 MGLL (0.37) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL3616721 0.82 MGLL (0.77) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL18350795 0.81 MGLL (0.59) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL16060512 0.81 MGLL (0.59) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL258626 0.79 MGLL (1.00) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL818349 0.79 MGLL (1.00) MGLLFAAHALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4683972-A1 SILICON PHTHALOCYANINE AND TRIBENZOPHTHALOCYANINE DYES AND THEIR USE IN DIAGNOSIS AND THERAPY Albert-Ludwigs-Universität Freiburg (DE) 2026-01-28 EP disclosed
WO-2024194415-A1 SILICON PHTHALOCYANINE AND TRIBENZOPHTHALOCYANINE DYES AND THEIR USE IN DIAGNOSIS AND THERAPY ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2024-09-26 WO disclosed
EP-4435060-A1 SILICON PHTHALOCYANINE AND TRIBENZOPHTHALOCYANINE DYES AND THEIR USE IN DIAGNOSIS AND THERAPY Albert-Ludwigs-Universität Freiburg (DE) 2024-09-25 EP disclosed
US-11572379-B2 Monomaleimide-functionalized platinum compounds for cancer therapy MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2023-02-07 US disclosed
US-11572379-B2 Monomaleimide-functionalized platinum compounds for cancer therapy MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2023-02-07 US disclosed
CN-108368143-B Monomaleimide functionalized platinum compounds for cancer therapy 维也纳医科大学 2022-02-01 CN disclosed
US-20210228530-A1 TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF SANTOLECAN PHARMACEUTICALS LLC 2021-07-29 US disclosed
EP-3386997-B1 MONOMALEIMIDE-FUNCTIONALIZED PLATINUM COMPOUNDS FOR CANCER THERAPY UNIV WIEN MED (AT) 2021-06-30 EP disclosed
EP-3386997-B1 MONOMALEIMIDE-FUNCTIONALIZED PLATINUM COMPOUNDS FOR CANCER THERAPY UNIV WIEN MED (AT) 2021-06-30 EP disclosed
EP-3157515-B1 PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF PLACON THERAPEUTICS INC (US) 2021-05-26 EP disclosed
WO-2004101550-A1 OXETANE COMPOUNDS CONTAINING MALEIMIDE FUNCTIONALITY NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) 2004-11-25 WO disclosed
WO-2004101646-A1 ADHESIVE COMPOSITIONS CONTAINING HYBRID OXETANE COMPOUNDS NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) 2004-11-25 WO disclosed
US-20040225070-A1 Oxetane compounds containing maleimide functionality HENKEL AG & CO. KGAA (DE) 2004-11-11 US disclosed
US-20040225074-A1 Adhesive compositions containing hybrid oxetane compounds HENKEL AG & CO. KGAA (DE) 2004-11-11 US disclosed
EP-0888389-B1 PHOTOACTIVATABLE CHAIN TRANSFER AGENTS SURMODICS INC (US) 2004-08-04 EP disclosed
WO-2004012735-A2 NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE SCHERING AG (DE) 2004-02-12 WO disclosed
EP-0888389-A4 PHOTOACTIVATABLE CHAIN TRANSFER AGENTS SURMODICS INC (US) 2001-03-14 EP disclosed
US-5942555-A Photoactivatable chain transfer agents and semi-telechelic photoactivatable polymers prepared therefrom SURMODICS, INC. (US) 1999-08-24 US disclosed
EP-0888389-A1 PHOTOACTIVATABLE CHAIN TRANSFER AGENTS SurModics, Inc. (US) 1999-01-07 EP disclosed
WO-1997034935-A1 PHOTOACTIVATABLE CHAIN TRANSFER AGENTS BSI CORPORATION (US) 1997-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210228530-A1 TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF DDOST, UGT2B17, UGT1A7 MGLL 1285/4885FAAH 2384/4885ALDH1A1 345/4885
US-11572379-B2 Monomaleimide-functionalized platinum compounds for cancer therapy FOLR2, FOLR1, SLC19A1 MGLL 3581/4885FAAH 3461/4885ALDH1A1 982/4885
US-20040225070-A1 Oxetane compounds containing maleimide functionality OXGR1, DUOX2, JMJD6 MGLL 3680/4885FAAH 870/4885ALDH1A1 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.